| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Percutaneous Coronary Intervention | 97 | 2024 | 298 | 23.090 |
Why?
|
| Coronary Occlusion | 58 | 2023 | 78 | 13.340 |
Why?
|
| Coronary Artery Disease | 42 | 2024 | 271 | 13.200 |
Why?
|
| Fractional Flow Reserve, Myocardial | 39 | 2023 | 126 | 11.940 |
Why?
|
| Angioplasty, Balloon, Coronary | 55 | 2020 | 137 | 11.420 |
Why?
|
| Coronary Angiography | 115 | 2023 | 353 | 9.130 |
Why?
|
| Stents | 54 | 2023 | 345 | 9.040 |
Why?
|
| Coronary Vessels | 37 | 2024 | 157 | 8.110 |
Why?
|
| Coronary Stenosis | 22 | 2021 | 99 | 6.480 |
Why?
|
| Myocardial Infarction | 52 | 2024 | 389 | 5.560 |
Why?
|
| Drug-Eluting Stents | 22 | 2023 | 92 | 5.130 |
Why?
|
| Treatment Outcome | 129 | 2024 | 5165 | 4.840 |
Why?
|
| Cardiac Catheterization | 33 | 2023 | 213 | 4.280 |
Why?
|
| Heart Failure | 58 | 2021 | 505 | 3.410 |
Why?
|
| Coronary Artery Bypass | 19 | 2022 | 122 | 3.190 |
Why?
|
| Humans | 333 | 2024 | 49863 | 3.060 |
Why?
|
| Acute Coronary Syndrome | 8 | 2022 | 78 | 2.970 |
Why?
|
| Chronic Disease | 55 | 2023 | 563 | 2.520 |
Why?
|
| Tomography, Optical Coherence | 8 | 2018 | 104 | 2.390 |
Why?
|
| Coronary Disease | 27 | 2015 | 152 | 2.330 |
Why?
|
| Saphenous Vein | 14 | 2021 | 63 | 2.300 |
Why?
|
| Risk Factors | 78 | 2023 | 3597 | 2.250 |
Why?
|
| Graft Occlusion, Vascular | 13 | 2021 | 74 | 2.190 |
Why?
|
| Platelet Aggregation Inhibitors | 12 | 2014 | 174 | 2.170 |
Why?
|
| Coronary Thrombosis | 9 | 2020 | 24 | 2.130 |
Why?
|
| Male | 193 | 2024 | 25439 | 2.080 |
Why?
|
| Myocardial Ischemia | 13 | 2020 | 117 | 1.880 |
Why?
|
| Cardiology | 14 | 2019 | 87 | 1.870 |
Why?
|
| Predictive Value of Tests | 28 | 2023 | 907 | 1.860 |
Why?
|
| Registries | 33 | 2023 | 522 | 1.860 |
Why?
|
| Aged | 105 | 2023 | 9434 | 1.840 |
Why?
|
| Middle Aged | 147 | 2024 | 12258 | 1.830 |
Why?
|
| Coronary Restenosis | 8 | 2021 | 31 | 1.750 |
Why?
|
| Thrombosis | 11 | 2018 | 249 | 1.740 |
Why?
|
| Myocardium | 20 | 2013 | 439 | 1.680 |
Why?
|
| Time Factors | 53 | 2023 | 2889 | 1.650 |
Why?
|
| Heptanoic Acids | 15 | 2008 | 34 | 1.590 |
Why?
|
| Pyrroles | 15 | 2008 | 68 | 1.550 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 13 | 2022 | 137 | 1.480 |
Why?
|
| Risk Assessment | 30 | 2023 | 1253 | 1.470 |
Why?
|
| Female | 146 | 2024 | 26520 | 1.410 |
Why?
|
| Heart Injuries | 3 | 2019 | 15 | 1.410 |
Why?
|
| Cardiac Tamponade | 4 | 2024 | 27 | 1.320 |
Why?
|
| Ventricular Function, Left | 16 | 2023 | 158 | 1.320 |
Why?
|
| Cardiotonic Agents | 23 | 2019 | 82 | 1.320 |
Why?
|
| Myocardial Reperfusion Injury | 10 | 2011 | 48 | 1.270 |
Why?
|
| Hemodynamics | 41 | 2018 | 264 | 1.250 |
Why?
|
| Postoperative Complications | 18 | 2019 | 1000 | 1.210 |
Why?
|
| Collateral Circulation | 10 | 2020 | 39 | 1.180 |
Why?
|
| Heart Transplantation | 31 | 2009 | 344 | 1.170 |
Why?
|
| Vasodilator Agents | 8 | 2016 | 98 | 1.140 |
Why?
|
| Coronary Circulation | 11 | 2024 | 59 | 1.090 |
Why?
|
| Societies, Medical | 10 | 2019 | 176 | 1.080 |
Why?
|
| Heart-Assist Devices | 4 | 2020 | 150 | 1.080 |
Why?
|
| Ventricular Dysfunction, Left | 9 | 2018 | 100 | 1.030 |
Why?
|
| Contrast Media | 9 | 2018 | 186 | 1.010 |
Why?
|
| Prosthesis Design | 11 | 2021 | 237 | 0.990 |
Why?
|
| Cardiac Catheters | 4 | 2020 | 12 | 0.990 |
Why?
|
| Thrombolytic Therapy | 2 | 2020 | 110 | 0.980 |
Why?
|
| Death, Sudden, Cardiac | 6 | 2008 | 57 | 0.940 |
Why?
|
| Pericarditis | 2 | 2022 | 20 | 0.940 |
Why?
|
| Algorithms | 6 | 2021 | 613 | 0.910 |
Why?
|
| Adenosine | 7 | 2018 | 70 | 0.910 |
Why?
|
| Balloon Occlusion | 1 | 2024 | 17 | 0.910 |
Why?
|
| Pericardial Effusion | 1 | 2024 | 39 | 0.890 |
Why?
|
| Hemorrhage | 4 | 2019 | 194 | 0.880 |
Why?
|
| Digitalis | 2 | 2021 | 5 | 0.870 |
Why?
|
| Cardiovascular Agents | 5 | 2009 | 54 | 0.860 |
Why?
|
| Occupational Health | 1 | 2023 | 66 | 0.840 |
Why?
|
| Aneurysm, False | 5 | 2020 | 43 | 0.840 |
Why?
|
| Pericarditis, Constrictive | 1 | 2022 | 2 | 0.840 |
Why?
|
| Retrospective Studies | 32 | 2020 | 6106 | 0.810 |
Why?
|
| Digoxin | 12 | 2021 | 30 | 0.810 |
Why?
|
| Aorta | 4 | 2019 | 162 | 0.810 |
Why?
|
| Hypotension, Controlled | 1 | 2021 | 3 | 0.790 |
Why?
|
| Radiography, Interventional | 7 | 2018 | 57 | 0.780 |
Why?
|
| Anemia | 1 | 2022 | 66 | 0.770 |
Why?
|
| Angina, Unstable | 8 | 2016 | 22 | 0.750 |
Why?
|
| Thrombocytopenia | 1 | 2022 | 79 | 0.750 |
Why?
|
| Mammary Arteries | 3 | 2017 | 8 | 0.750 |
Why?
|
| Follow-Up Studies | 27 | 2019 | 2174 | 0.740 |
Why?
|
| Absorbable Implants | 2 | 2022 | 16 | 0.740 |
Why?
|
| Prognosis | 19 | 2023 | 1948 | 0.740 |
Why?
|
| Inferior Wall Myocardial Infarction | 1 | 2020 | 1 | 0.730 |
Why?
|
| Thiazolidinediones | 6 | 2008 | 82 | 0.710 |
Why?
|
| Time-to-Treatment | 2 | 2020 | 69 | 0.710 |
Why?
|
| Shock, Cardiogenic | 1 | 2020 | 25 | 0.700 |
Why?
|
| Cardiovascular Diseases | 11 | 2015 | 443 | 0.680 |
Why?
|
| Stroke Volume | 18 | 2023 | 130 | 0.680 |
Why?
|
| Diabetic Angiopathies | 2 | 2013 | 17 | 0.680 |
Why?
|
| Heart Ventricles | 8 | 2012 | 250 | 0.670 |
Why?
|
| Prospective Studies | 28 | 2023 | 2341 | 0.670 |
Why?
|
| Enbucrilate | 1 | 2019 | 6 | 0.670 |
Why?
|
| Tissue Adhesives | 1 | 2019 | 13 | 0.670 |
Why?
|
| Practice Guidelines as Topic | 3 | 2020 | 454 | 0.670 |
Why?
|
| Arterial Pressure | 1 | 2019 | 44 | 0.670 |
Why?
|
| Hyperemia | 3 | 2016 | 18 | 0.660 |
Why?
|
| Pericardium | 4 | 2022 | 28 | 0.660 |
Why?
|
| Operative Time | 3 | 2019 | 71 | 0.650 |
Why?
|
| Guideline Adherence | 1 | 2020 | 133 | 0.650 |
Why?
|
| Adrenergic beta-Antagonists | 5 | 2008 | 105 | 0.640 |
Why?
|
| Aspirin | 5 | 2022 | 113 | 0.620 |
Why?
|
| Hematoma | 2 | 2013 | 64 | 0.620 |
Why?
|
| Troponin T | 3 | 2011 | 13 | 0.620 |
Why?
|
| Electrocardiography | 16 | 2022 | 259 | 0.610 |
Why?
|
| Severity of Illness Index | 19 | 2019 | 953 | 0.610 |
Why?
|
| Heart Septum | 3 | 2010 | 23 | 0.600 |
Why?
|
| Hydrostatic Pressure | 1 | 2017 | 7 | 0.590 |
Why?
|
| Angioplasty, Balloon | 4 | 2022 | 66 | 0.580 |
Why?
|
| Perioperative Care | 5 | 2015 | 42 | 0.580 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 10 | 2011 | 74 | 0.580 |
Why?
|
| Creatine Kinase, MB Form | 3 | 2013 | 6 | 0.580 |
Why?
|
| Surgical Procedures, Operative | 4 | 2015 | 66 | 0.560 |
Why?
|
| Foramen Ovale, Patent | 2 | 2014 | 27 | 0.560 |
Why?
|
| Defibrillators, Implantable | 5 | 2007 | 63 | 0.560 |
Why?
|
| United States | 28 | 2022 | 4870 | 0.550 |
Why?
|
| Purinergic P2Y Receptor Antagonists | 2 | 2014 | 29 | 0.540 |
Why?
|
| Randomized Controlled Trials as Topic | 13 | 2021 | 548 | 0.540 |
Why?
|
| Propranolol | 3 | 2008 | 78 | 0.530 |
Why?
|
| Kidney Failure, Chronic | 4 | 2004 | 198 | 0.530 |
Why?
|
| Heart | 10 | 2006 | 330 | 0.520 |
Why?
|
| Veterans | 1 | 2022 | 564 | 0.520 |
Why?
|
| Tissue Donors | 2 | 2013 | 110 | 0.520 |
Why?
|
| Alloys | 2 | 2020 | 9 | 0.510 |
Why?
|
| Incidence | 16 | 2018 | 982 | 0.510 |
Why?
|
| Heart Rupture, Post-Infarction | 3 | 2005 | 4 | 0.500 |
Why?
|
| Aortic Valve | 3 | 2022 | 109 | 0.490 |
Why?
|
| Physician-Patient Relations | 2 | 2015 | 143 | 0.490 |
Why?
|
| Fibrinolytic Agents | 3 | 2014 | 125 | 0.490 |
Why?
|
| Vascular System Injuries | 1 | 2015 | 37 | 0.480 |
Why?
|
| Wounds, Penetrating | 1 | 2015 | 40 | 0.480 |
Why?
|
| Tomography, X-Ray Computed | 5 | 2013 | 1152 | 0.480 |
Why?
|
| Ultrasonography, Interventional | 7 | 2013 | 137 | 0.470 |
Why?
|
| Purines | 2 | 2014 | 38 | 0.460 |
Why?
|
| Adenosine A2 Receptor Agonists | 1 | 2014 | 5 | 0.460 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 3 | 2009 | 32 | 0.460 |
Why?
|
| Lisinopril | 7 | 2003 | 13 | 0.460 |
Why?
|
| Anterior Wall Myocardial Infarction | 2 | 2012 | 7 | 0.450 |
Why?
|
| Computer-Assisted Instruction | 1 | 2014 | 30 | 0.450 |
Why?
|
| Clinical Trials as Topic | 9 | 2012 | 463 | 0.450 |
Why?
|
| Metals | 2 | 2011 | 35 | 0.450 |
Why?
|
| Cyclooxygenase 2 | 8 | 2008 | 45 | 0.450 |
Why?
|
| Piperazines | 2 | 2012 | 118 | 0.440 |
Why?
|
| Pyrazoles | 2 | 2014 | 114 | 0.440 |
Why?
|
| Blood Vessel Prosthesis Implantation | 4 | 2009 | 121 | 0.440 |
Why?
|
| Anticholesteremic Agents | 3 | 2008 | 28 | 0.440 |
Why?
|
| Mentors | 1 | 2014 | 55 | 0.440 |
Why?
|
| Coronary Vessel Anomalies | 3 | 2017 | 38 | 0.440 |
Why?
|
| Arteries | 1 | 2013 | 91 | 0.440 |
Why?
|
| Atrial Function, Left | 1 | 2013 | 4 | 0.430 |
Why?
|
| Endarterectomy, Carotid | 2 | 2011 | 62 | 0.430 |
Why?
|
| Lipoxins | 3 | 2008 | 3 | 0.430 |
Why?
|
| Cardiac Surgical Procedures | 3 | 2014 | 298 | 0.430 |
Why?
|
| Imidazoles | 9 | 1990 | 128 | 0.420 |
Why?
|
| Drug Administration Schedule | 7 | 2014 | 370 | 0.420 |
Why?
|
| Coronary Aneurysm | 2 | 2007 | 18 | 0.420 |
Why?
|
| Pressure | 4 | 2017 | 105 | 0.420 |
Why?
|
| Drug Eruptions | 1 | 2012 | 13 | 0.410 |
Why?
|
| Rats, Sprague-Dawley | 14 | 2008 | 1574 | 0.410 |
Why?
|
| Physicians | 2 | 2015 | 227 | 0.410 |
Why?
|
| Thiophenes | 1 | 2012 | 36 | 0.410 |
Why?
|
| Rats | 19 | 2011 | 3293 | 0.400 |
Why?
|
| Stroke | 3 | 2013 | 479 | 0.400 |
Why?
|
| Double-Blind Method | 14 | 2020 | 678 | 0.390 |
Why?
|
| Embolism | 2 | 2013 | 20 | 0.390 |
Why?
|
| Quality Assurance, Health Care | 4 | 2012 | 149 | 0.390 |
Why?
|
| Cyclooxygenase Inhibitors | 5 | 2007 | 39 | 0.390 |
Why?
|
| Diverticulum | 1 | 2011 | 21 | 0.380 |
Why?
|
| Internet | 1 | 2014 | 259 | 0.380 |
Why?
|
| Troponin I | 1 | 2011 | 18 | 0.380 |
Why?
|
| Transurethral Resection of Prostate | 1 | 2011 | 10 | 0.380 |
Why?
|
| Intraoperative Complications | 4 | 2020 | 112 | 0.370 |
Why?
|
| Carotid Arteries | 1 | 2011 | 82 | 0.370 |
Why?
|
| Myocytes, Cardiac | 5 | 2011 | 122 | 0.370 |
Why?
|
| Receptors, Adrenergic, beta-2 | 2 | 2009 | 16 | 0.370 |
Why?
|
| Embolic Protection Devices | 1 | 2010 | 6 | 0.370 |
Why?
|
| Paclitaxel | 1 | 2011 | 83 | 0.370 |
Why?
|
| Receptors, Opioid, delta | 2 | 2009 | 25 | 0.370 |
Why?
|
| Clinical Competence | 4 | 2013 | 393 | 0.360 |
Why?
|
| Pericardiectomy | 2 | 2024 | 6 | 0.360 |
Why?
|
| Mitral Valve | 1 | 2010 | 50 | 0.350 |
Why?
|
| Endocarditis | 1 | 2010 | 31 | 0.350 |
Why?
|
| Adult | 49 | 2019 | 13325 | 0.350 |
Why?
|
| Kaplan-Meier Estimate | 6 | 2017 | 463 | 0.350 |
Why?
|
| Calcinosis | 4 | 2023 | 52 | 0.340 |
Why?
|
| Anticoagulants | 6 | 2024 | 253 | 0.340 |
Why?
|
| Cardiac Output, Low | 5 | 2006 | 11 | 0.330 |
Why?
|
| Suction | 2 | 2008 | 23 | 0.330 |
Why?
|
| Sirolimus | 2 | 2009 | 62 | 0.330 |
Why?
|
| Echocardiography, Transesophageal | 2 | 2006 | 60 | 0.330 |
Why?
|
| Hypoglycemic Agents | 3 | 2006 | 169 | 0.330 |
Why?
|
| Heart Valve Prosthesis | 3 | 2022 | 76 | 0.320 |
Why?
|
| Carotid Artery, Common | 2 | 2006 | 44 | 0.320 |
Why?
|
| Myocardial Bridging | 1 | 2008 | 2 | 0.310 |
Why?
|
| Heart Failure, Systolic | 1 | 2008 | 7 | 0.310 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2009 | 110 | 0.310 |
Why?
|
| Aortic Valve Stenosis | 3 | 2022 | 60 | 0.310 |
Why?
|
| Peptides | 2 | 2008 | 224 | 0.310 |
Why?
|
| Azetidines | 1 | 2008 | 6 | 0.310 |
Why?
|
| Creatinine | 3 | 2004 | 140 | 0.300 |
Why?
|
| Consensus | 2 | 2007 | 156 | 0.300 |
Why?
|
| Patient Selection | 7 | 2012 | 253 | 0.300 |
Why?
|
| Exercise Test | 10 | 2002 | 129 | 0.300 |
Why?
|
| Survival Analysis | 13 | 2010 | 669 | 0.300 |
Why?
|
| Heart Septal Defects, Atrial | 2 | 2013 | 43 | 0.290 |
Why?
|
| Telemedicine | 1 | 2014 | 465 | 0.290 |
Why?
|
| Animals | 28 | 2022 | 13133 | 0.290 |
Why?
|
| Drug Therapy, Combination | 10 | 2008 | 380 | 0.290 |
Why?
|
| Proportional Hazards Models | 10 | 2017 | 404 | 0.290 |
Why?
|
| Vascular Patency | 5 | 2020 | 83 | 0.290 |
Why?
|
| Mitral Valve Insufficiency | 3 | 2007 | 45 | 0.280 |
Why?
|
| Aortic Valve Insufficiency | 2 | 2016 | 20 | 0.280 |
Why?
|
| Laboratories, Hospital | 1 | 2006 | 6 | 0.280 |
Why?
|
| Terminology as Topic | 3 | 2013 | 63 | 0.280 |
Why?
|
| Pacemaker, Artificial | 1 | 2007 | 32 | 0.270 |
Why?
|
| Echocardiography, Three-Dimensional | 1 | 2006 | 12 | 0.270 |
Why?
|
| Chi-Square Distribution | 3 | 2017 | 275 | 0.270 |
Why?
|
| Bacteremia | 1 | 2007 | 90 | 0.260 |
Why?
|
| Inpatients | 2 | 2018 | 191 | 0.260 |
Why?
|
| Gadolinium DTPA | 1 | 2005 | 25 | 0.260 |
Why?
|
| Chest Pain | 3 | 2006 | 55 | 0.250 |
Why?
|
| Lipopolysaccharides | 1 | 2006 | 195 | 0.250 |
Why?
|
| Nitric Oxide Synthase Type III | 6 | 2008 | 78 | 0.250 |
Why?
|
| Carotid Artery Diseases | 1 | 2005 | 32 | 0.250 |
Why?
|
| Neovascularization, Physiologic | 2 | 2005 | 68 | 0.250 |
Why?
|
| Angina, Stable | 2 | 2016 | 7 | 0.250 |
Why?
|
| Europe | 8 | 2019 | 75 | 0.250 |
Why?
|
| Prostaglandins | 1 | 2005 | 20 | 0.250 |
Why?
|
| Risk | 8 | 2011 | 313 | 0.250 |
Why?
|
| Arginine Vasopressin | 6 | 2005 | 13 | 0.250 |
Why?
|
| Calcium | 1 | 2007 | 398 | 0.240 |
Why?
|
| Atrial Fibrillation | 4 | 2021 | 182 | 0.240 |
Why?
|
| Pain Management | 3 | 2015 | 164 | 0.240 |
Why?
|
| Program Evaluation | 1 | 2006 | 349 | 0.240 |
Why?
|
| Dobutamine | 6 | 1999 | 22 | 0.240 |
Why?
|
| Renal Insufficiency | 1 | 2005 | 107 | 0.240 |
Why?
|
| Chemokine CCL2 | 1 | 2004 | 71 | 0.240 |
Why?
|
| Dose-Response Relationship, Drug | 12 | 2017 | 1354 | 0.240 |
Why?
|
| Metabolic Clearance Rate | 1 | 2004 | 69 | 0.240 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2004 | 6 | 0.240 |
Why?
|
| Equipment Design | 4 | 2020 | 284 | 0.240 |
Why?
|
| Recurrence | 8 | 2016 | 658 | 0.230 |
Why?
|
| History, 21st Century | 2 | 2019 | 56 | 0.230 |
Why?
|
| Pericardiocentesis | 1 | 2024 | 15 | 0.230 |
Why?
|
| Angiography | 7 | 2012 | 127 | 0.230 |
Why?
|
| Femoral Artery | 4 | 2019 | 102 | 0.230 |
Why?
|
| Monocytes | 1 | 2004 | 131 | 0.230 |
Why?
|
| History, 20th Century | 2 | 2019 | 95 | 0.230 |
Why?
|
| Secondary Prevention | 2 | 2015 | 78 | 0.230 |
Why?
|
| Artifacts | 1 | 2004 | 53 | 0.230 |
Why?
|
| Reoperation | 5 | 2013 | 451 | 0.230 |
Why?
|
| Reproducibility of Results | 6 | 2016 | 1180 | 0.230 |
Why?
|
| Staphylococcal Infections | 1 | 2007 | 269 | 0.220 |
Why?
|
| Cardiomyopathy, Hypertrophic | 1 | 2004 | 29 | 0.220 |
Why?
|
| Angina Pectoris | 4 | 2020 | 20 | 0.220 |
Why?
|
| Nitric Oxide Synthase Type II | 4 | 2008 | 66 | 0.220 |
Why?
|
| Disease Models, Animal | 10 | 2011 | 1448 | 0.220 |
Why?
|
| Aged, 80 and over | 10 | 2017 | 3132 | 0.220 |
Why?
|
| Catheterization | 4 | 2019 | 99 | 0.210 |
Why?
|
| Materials Testing | 2 | 2020 | 56 | 0.210 |
Why?
|
| American Heart Association | 4 | 2015 | 32 | 0.210 |
Why?
|
| Hospital Mortality | 5 | 2019 | 409 | 0.210 |
Why?
|
| Anti-Arrhythmia Agents | 4 | 2004 | 81 | 0.200 |
Why?
|
| Body Composition | 1 | 2004 | 320 | 0.200 |
Why?
|
| Cyclosporins | 5 | 1989 | 9 | 0.200 |
Why?
|
| Vasodilation | 2 | 2021 | 96 | 0.200 |
Why?
|
| Constriction, Pathologic | 3 | 2017 | 95 | 0.200 |
Why?
|
| Exercise Tolerance | 5 | 1997 | 40 | 0.200 |
Why?
|
| Odds Ratio | 4 | 2016 | 547 | 0.200 |
Why?
|
| Propanolamines | 3 | 2011 | 14 | 0.200 |
Why?
|
| Retreatment | 2 | 2012 | 56 | 0.190 |
Why?
|
| Epoprostenol | 5 | 2001 | 25 | 0.180 |
Why?
|
| Heart Valve Prosthesis Implantation | 2 | 2016 | 78 | 0.180 |
Why?
|
| Diet, Sodium-Restricted | 1 | 2000 | 5 | 0.180 |
Why?
|
| Enalapril | 3 | 1989 | 15 | 0.180 |
Why?
|
| Up-Regulation | 4 | 2011 | 448 | 0.180 |
Why?
|
| Cardiomyopathies | 9 | 2003 | 114 | 0.180 |
Why?
|
| Hospitalization | 5 | 2011 | 663 | 0.180 |
Why?
|
| Administration, Oral | 9 | 2015 | 432 | 0.180 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2022 | 287 | 0.180 |
Why?
|
| Ischemia | 1 | 2021 | 153 | 0.180 |
Why?
|
| Logistic Models | 5 | 2018 | 895 | 0.180 |
Why?
|
| Angioplasty | 1 | 2020 | 20 | 0.170 |
Why?
|
| Calcitonin Gene-Related Peptide | 2 | 2009 | 23 | 0.170 |
Why?
|
| Plaque, Atherosclerotic | 1 | 2019 | 37 | 0.170 |
Why?
|
| 6-Ketoprostaglandin F1 alpha | 3 | 2008 | 6 | 0.170 |
Why?
|
| Life Style | 1 | 2000 | 140 | 0.170 |
Why?
|
| Heart Rate | 7 | 1993 | 298 | 0.160 |
Why?
|
| Specialization | 1 | 2019 | 46 | 0.160 |
Why?
|
| Atherectomy | 1 | 2019 | 13 | 0.160 |
Why?
|
| Atrial Natriuretic Factor | 4 | 1996 | 25 | 0.160 |
Why?
|
| Quality Improvement | 2 | 2011 | 205 | 0.160 |
Why?
|
| Russia | 4 | 2019 | 10 | 0.160 |
Why?
|
| Cost-Benefit Analysis | 2 | 2014 | 269 | 0.160 |
Why?
|
| Radial Artery | 1 | 2019 | 29 | 0.160 |
Why?
|
| Prevalence | 5 | 2018 | 951 | 0.160 |
Why?
|
| Peripheral Arterial Disease | 1 | 2019 | 66 | 0.160 |
Why?
|
| Proto-Oncogene Proteins c-akt | 3 | 2009 | 156 | 0.160 |
Why?
|
| Multivariate Analysis | 7 | 2016 | 577 | 0.160 |
Why?
|
| Catheterization, Peripheral | 1 | 2019 | 46 | 0.160 |
Why?
|
| Feasibility Studies | 2 | 2020 | 382 | 0.160 |
Why?
|
| Patient Care Planning | 1 | 2019 | 67 | 0.150 |
Why?
|
| Tachycardia, Ventricular | 2 | 2004 | 43 | 0.150 |
Why?
|
| Pulmonary Wedge Pressure | 8 | 2001 | 27 | 0.150 |
Why?
|
| Patient Care | 1 | 1998 | 57 | 0.150 |
Why?
|
| Emergency Medical Services | 1 | 2019 | 110 | 0.150 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2004 | 480 | 0.150 |
Why?
|
| Patient Safety | 1 | 2018 | 102 | 0.150 |
Why?
|
| Medicare | 2 | 2011 | 245 | 0.150 |
Why?
|
| Fistula | 2 | 1996 | 26 | 0.150 |
Why?
|
| Intra-Aortic Balloon Pumping | 2 | 1994 | 7 | 0.150 |
Why?
|
| Blood Pressure | 12 | 1997 | 517 | 0.150 |
Why?
|
| Education, Medical | 1 | 2019 | 112 | 0.150 |
Why?
|
| Waiting Lists | 3 | 2007 | 54 | 0.150 |
Why?
|
| Antihypertensive Agents | 4 | 2001 | 124 | 0.140 |
Why?
|
| Cardiac Pacing, Artificial | 3 | 2008 | 28 | 0.140 |
Why?
|
| Adventitia | 1 | 2017 | 4 | 0.140 |
Why?
|
| Education, Medical, Graduate | 3 | 2013 | 210 | 0.140 |
Why?
|
| Curriculum | 3 | 2013 | 397 | 0.140 |
Why?
|
| Renin | 5 | 1996 | 19 | 0.140 |
Why?
|
| Enoximone | 9 | 1990 | 10 | 0.140 |
Why?
|
| Quality of Life | 5 | 2008 | 837 | 0.140 |
Why?
|
| Myocardial Revascularization | 3 | 2012 | 14 | 0.140 |
Why?
|
| Advisory Committees | 2 | 2014 | 61 | 0.140 |
Why?
|
| Norepinephrine | 6 | 1996 | 112 | 0.140 |
Why?
|
| Substance Withdrawal Syndrome | 2 | 1997 | 167 | 0.140 |
Why?
|
| Phosphorylation | 6 | 2008 | 526 | 0.140 |
Why?
|
| Nitric Oxide Synthase | 2 | 2008 | 75 | 0.140 |
Why?
|
| Propensity Score | 1 | 2017 | 123 | 0.130 |
Why?
|
| Hypertension, Pulmonary | 7 | 1997 | 121 | 0.130 |
Why?
|
| Treatment Failure | 4 | 2018 | 116 | 0.130 |
Why?
|
| Simvastatin | 2 | 2008 | 29 | 0.130 |
Why?
|
| Hypertension | 6 | 2011 | 531 | 0.130 |
Why?
|
| Health Personnel | 3 | 2007 | 252 | 0.130 |
Why?
|
| Benzazepines | 2 | 2006 | 19 | 0.130 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2018 | 170 | 0.130 |
Why?
|
| Phosphodiesterase Inhibitors | 4 | 2007 | 25 | 0.130 |
Why?
|
| Graft Rejection | 9 | 2009 | 168 | 0.130 |
Why?
|
| Muscle Contraction | 1 | 1996 | 111 | 0.120 |
Why?
|
| Disease Progression | 6 | 2008 | 822 | 0.120 |
Why?
|
| Postpericardiotomy Syndrome | 1 | 2015 | 4 | 0.120 |
Why?
|
| Diagnostic Techniques, Cardiovascular | 2 | 2012 | 4 | 0.120 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2022 | 1526 | 0.120 |
Why?
|
| Age Factors | 5 | 2021 | 1091 | 0.120 |
Why?
|
| Angioscopy | 1 | 1994 | 3 | 0.120 |
Why?
|
| Cardiomyopathy, Dilated | 3 | 1996 | 38 | 0.120 |
Why?
|
| Colchicine | 1 | 2015 | 24 | 0.120 |
Why?
|
| Smad3 Protein | 1 | 2014 | 9 | 0.120 |
Why?
|
| Systole | 4 | 2010 | 71 | 0.120 |
Why?
|
| Cholesterol, Dietary | 1 | 2014 | 19 | 0.120 |
Why?
|
| Th2 Cells | 1 | 2014 | 22 | 0.120 |
Why?
|
| Tunica Intima | 1 | 1994 | 55 | 0.120 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 3 | 2011 | 51 | 0.120 |
Why?
|
| Patient Care Management | 1 | 2014 | 18 | 0.120 |
Why?
|
| Venous Thrombosis | 1 | 2015 | 89 | 0.120 |
Why?
|
| Area Under Curve | 3 | 2022 | 178 | 0.120 |
Why?
|
| Myocardial Contraction | 4 | 2009 | 107 | 0.120 |
Why?
|
| Receptors, LDL | 1 | 2014 | 66 | 0.120 |
Why?
|
| Acute Disease | 5 | 2019 | 367 | 0.120 |
Why?
|
| Health Care Costs | 1 | 1995 | 168 | 0.120 |
Why?
|
| Cardiovascular System | 1 | 2014 | 49 | 0.120 |
Why?
|
| Cohort Studies | 6 | 2022 | 1400 | 0.120 |
Why?
|
| Punctures | 3 | 2019 | 47 | 0.120 |
Why?
|
| Diuretics | 4 | 1998 | 28 | 0.110 |
Why?
|
| Atherosclerosis | 2 | 2014 | 209 | 0.110 |
Why?
|
| Cardiac Output | 10 | 1997 | 45 | 0.110 |
Why?
|
| Thromboembolism | 1 | 2014 | 54 | 0.110 |
Why?
|
| Survival Rate | 6 | 2018 | 904 | 0.110 |
Why?
|
| Dependovirus | 1 | 2014 | 103 | 0.110 |
Why?
|
| Transfection | 1 | 2014 | 352 | 0.110 |
Why?
|
| Remote Consultation | 1 | 2014 | 29 | 0.110 |
Why?
|
| Drug Costs | 1 | 2014 | 39 | 0.110 |
Why?
|
| Quality Indicators, Health Care | 2 | 2011 | 86 | 0.110 |
Why?
|
| Arrhythmias, Cardiac | 2 | 2012 | 90 | 0.110 |
Why?
|
| Infusions, Intravenous | 8 | 2011 | 212 | 0.110 |
Why?
|
| Septal Occluder Device | 1 | 2013 | 30 | 0.110 |
Why?
|
| Case-Control Studies | 3 | 2013 | 1129 | 0.110 |
Why?
|
| Echocardiography, Doppler, Color | 1 | 2013 | 22 | 0.110 |
Why?
|
| Pulmonary Edema | 1 | 2013 | 19 | 0.110 |
Why?
|
| Echocardiography, Doppler | 2 | 2016 | 52 | 0.110 |
Why?
|
| Hypertrophy, Left Ventricular | 3 | 2009 | 39 | 0.110 |
Why?
|
| Signal Transduction | 3 | 2009 | 1605 | 0.110 |
Why?
|
| General Surgery | 1 | 2014 | 106 | 0.110 |
Why?
|
| Evidence-Based Medicine | 2 | 2011 | 247 | 0.110 |
Why?
|
| Heparin | 2 | 2024 | 92 | 0.100 |
Why?
|
| Cause of Death | 7 | 2007 | 145 | 0.100 |
Why?
|
| Pleural Effusion | 1 | 2013 | 38 | 0.100 |
Why?
|
| Kidney Diseases | 2 | 2007 | 211 | 0.100 |
Why?
|
| Ultrasonography | 3 | 2010 | 428 | 0.100 |
Why?
|
| Echocardiography | 7 | 2005 | 378 | 0.100 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2014 | 242 | 0.100 |
Why?
|
| Sex Factors | 5 | 2022 | 690 | 0.100 |
Why?
|
| Embolism, Cholesterol | 1 | 2011 | 2 | 0.100 |
Why?
|
| Carbazoles | 2 | 2005 | 16 | 0.100 |
Why?
|
| Creatine Kinase | 2 | 2003 | 30 | 0.100 |
Why?
|
| Cardiovascular Surgical Procedures | 2 | 2012 | 10 | 0.100 |
Why?
|
| Exercise | 1 | 1996 | 499 | 0.100 |
Why?
|
| Kidney | 4 | 2005 | 672 | 0.100 |
Why?
|
| Equipment Failure | 3 | 2008 | 63 | 0.100 |
Why?
|
| Random Allocation | 4 | 2005 | 285 | 0.100 |
Why?
|
| Milrinone | 1 | 2011 | 9 | 0.100 |
Why?
|
| Isoenzymes | 2 | 2003 | 169 | 0.100 |
Why?
|
| Death | 2 | 2022 | 21 | 0.090 |
Why?
|
| Insurance Claim Review | 1 | 2011 | 36 | 0.090 |
Why?
|
| Diabetes Complications | 3 | 2011 | 118 | 0.090 |
Why?
|
| Enkephalin, D-Penicillamine (2,5)- | 2 | 2009 | 3 | 0.090 |
Why?
|
| Unnecessary Procedures | 1 | 2011 | 20 | 0.090 |
Why?
|
| Prednisone | 3 | 1989 | 100 | 0.090 |
Why?
|
| Amrinone | 2 | 1987 | 2 | 0.090 |
Why?
|
| Oxygen Consumption | 5 | 1996 | 188 | 0.090 |
Why?
|
| Cells, Cultured | 5 | 2009 | 1579 | 0.090 |
Why?
|
| Body Weight | 3 | 2007 | 513 | 0.090 |
Why?
|
| Preoperative Care | 2 | 2007 | 167 | 0.090 |
Why?
|
| Thrombectomy | 1 | 2011 | 69 | 0.090 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 2 | 2007 | 19 | 0.090 |
Why?
|
| Injections, Intra-Arterial | 2 | 2015 | 13 | 0.090 |
Why?
|
| Necrosis | 1 | 2010 | 175 | 0.090 |
Why?
|
| Texas | 4 | 2006 | 141 | 0.090 |
Why?
|
| Surgical Instruments | 1 | 2010 | 27 | 0.090 |
Why?
|
| Disease Management | 3 | 2014 | 175 | 0.090 |
Why?
|
| Magnetic Resonance Imaging, Cine | 1 | 2010 | 59 | 0.090 |
Why?
|
| Endothelium, Vascular | 3 | 2007 | 253 | 0.090 |
Why?
|
| Diatrizoate | 1 | 1989 | 3 | 0.090 |
Why?
|
| Reperfusion Injury | 2 | 2007 | 87 | 0.090 |
Why?
|
| Iopamidol | 1 | 1989 | 2 | 0.080 |
Why?
|
| Receptors, Calcitonin Gene-Related Peptide | 1 | 2009 | 4 | 0.080 |
Why?
|
| Ethanolamines | 2 | 1986 | 13 | 0.080 |
Why?
|
| ROC Curve | 2 | 2022 | 224 | 0.080 |
Why?
|
| Hyperlipidemias | 2 | 2011 | 50 | 0.080 |
Why?
|
| Drug Administration Routes | 1 | 2008 | 11 | 0.080 |
Why?
|
| Leukotriene B4 | 1 | 2008 | 1 | 0.080 |
Why?
|
| Arachidonate 5-Lipoxygenase | 1 | 2008 | 4 | 0.080 |
Why?
|
| Fatal Outcome | 2 | 2007 | 194 | 0.080 |
Why?
|
| Hemostasis, Surgical | 1 | 2008 | 11 | 0.080 |
Why?
|
| Phospholipases A | 2 | 2006 | 13 | 0.080 |
Why?
|
| Phospholipases A2 | 2 | 2006 | 14 | 0.080 |
Why?
|
| Patient Transfer | 1 | 2009 | 94 | 0.080 |
Why?
|
| Comorbidity | 1 | 2010 | 607 | 0.080 |
Why?
|
| Meta-Analysis as Topic | 1 | 2008 | 38 | 0.080 |
Why?
|
| Drainage | 1 | 2008 | 79 | 0.080 |
Why?
|
| Analysis of Variance | 2 | 2008 | 553 | 0.080 |
Why?
|
| Heart Diseases | 3 | 2006 | 209 | 0.070 |
Why?
|
| Sulfonamides | 2 | 2008 | 127 | 0.070 |
Why?
|
| Myocardial Reperfusion | 1 | 2007 | 8 | 0.070 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2007 | 48 | 0.070 |
Why?
|
| Tetrazoles | 1 | 2007 | 40 | 0.070 |
Why?
|
| Dipyridamole | 1 | 2007 | 9 | 0.070 |
Why?
|
| Combined Modality Therapy | 1 | 2009 | 638 | 0.070 |
Why?
|
| Prosthesis Failure | 2 | 2012 | 108 | 0.070 |
Why?
|
| Microinjections | 2 | 2018 | 32 | 0.070 |
Why?
|
| Prostaglandin D2 | 1 | 2007 | 21 | 0.070 |
Why?
|
| Cyclooxygenase 1 | 1 | 2007 | 5 | 0.070 |
Why?
|
| Drug Interactions | 2 | 2007 | 208 | 0.070 |
Why?
|
| Thoracic Surgery | 1 | 2007 | 16 | 0.070 |
Why?
|
| Patient Admission | 1 | 2007 | 73 | 0.070 |
Why?
|
| Nitroso Compounds | 1 | 2006 | 4 | 0.070 |
Why?
|
| Calcium Signaling | 1 | 2007 | 56 | 0.070 |
Why?
|
| Enzyme Induction | 1 | 2006 | 79 | 0.070 |
Why?
|
| Mass Screening | 2 | 2004 | 346 | 0.070 |
Why?
|
| Anemia, Macrocytic | 1 | 1986 | 2 | 0.070 |
Why?
|
| Deferoxamine | 1 | 1986 | 10 | 0.070 |
Why?
|
| Anemia, Megaloblastic | 1 | 1986 | 3 | 0.070 |
Why?
|
| PPAR gamma | 1 | 2007 | 72 | 0.070 |
Why?
|
| Biotin | 1 | 2006 | 46 | 0.070 |
Why?
|
| Ubiquinone | 1 | 2006 | 12 | 0.070 |
Why?
|
| NF-kappa B | 1 | 2008 | 315 | 0.070 |
Why?
|
| Hemofiltration | 1 | 2006 | 7 | 0.070 |
Why?
|
| Magnesium | 1 | 2006 | 36 | 0.070 |
Why?
|
| Multicenter Studies as Topic | 4 | 2005 | 89 | 0.070 |
Why?
|
| Electric Countershock | 1 | 2006 | 30 | 0.070 |
Why?
|
| Heart Atria | 1 | 2006 | 57 | 0.070 |
Why?
|
| Forecasting | 1 | 2007 | 145 | 0.070 |
Why?
|
| Intracranial Embolism | 1 | 2006 | 27 | 0.070 |
Why?
|
| Patient Education as Topic | 2 | 2000 | 311 | 0.070 |
Why?
|
| Diagnosis, Differential | 2 | 2012 | 1038 | 0.070 |
Why?
|
| Radiology | 1 | 2008 | 130 | 0.070 |
Why?
|
| Ischemic Preconditioning | 1 | 2005 | 4 | 0.070 |
Why?
|
| Aortic Rupture | 1 | 2006 | 18 | 0.070 |
Why?
|
| Triiodobenzoic Acids | 1 | 2005 | 9 | 0.060 |
Why?
|
| Partnership Practice | 1 | 2005 | 1 | 0.060 |
Why?
|
| Myocardial Stunning | 1 | 2005 | 1 | 0.060 |
Why?
|
| Organizational Affiliation | 1 | 2005 | 2 | 0.060 |
Why?
|
| Health Planning | 1 | 2005 | 13 | 0.060 |
Why?
|
| Foreign Bodies | 1 | 2006 | 64 | 0.060 |
Why?
|
| Metoprolol | 1 | 2005 | 13 | 0.060 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2006 | 79 | 0.060 |
Why?
|
| Pyrrolidines | 1 | 2006 | 67 | 0.060 |
Why?
|
| Device Removal | 1 | 2006 | 84 | 0.060 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2006 | 124 | 0.060 |
Why?
|
| Iron | 1 | 1986 | 123 | 0.060 |
Why?
|
| Aortic Coarctation | 1 | 2006 | 33 | 0.060 |
Why?
|
| Sensitivity and Specificity | 3 | 2006 | 855 | 0.060 |
Why?
|
| Water-Electrolyte Balance | 1 | 1985 | 20 | 0.060 |
Why?
|
| Accidents, Traffic | 1 | 2006 | 87 | 0.060 |
Why?
|
| Isoxazoles | 1 | 2005 | 14 | 0.060 |
Why?
|
| Education, Medical, Continuing | 1 | 2005 | 68 | 0.060 |
Why?
|
| Intramolecular Oxidoreductases | 1 | 2005 | 14 | 0.060 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 2005 | 26 | 0.060 |
Why?
|
| Tetralogy of Fallot | 1 | 2006 | 81 | 0.060 |
Why?
|
| Ephedrine | 1 | 2004 | 21 | 0.060 |
Why?
|
| Regional Blood Flow | 1 | 2004 | 108 | 0.060 |
Why?
|
| Hyperhomocysteinemia | 1 | 2004 | 29 | 0.060 |
Why?
|
| Leadership | 1 | 2005 | 101 | 0.060 |
Why?
|
| Body Surface Area | 1 | 2004 | 26 | 0.060 |
Why?
|
| Membrane Proteins | 1 | 2007 | 347 | 0.060 |
Why?
|
| Polyethylene Terephthalates | 1 | 2004 | 10 | 0.060 |
Why?
|
| Brachiocephalic Trunk | 1 | 2004 | 6 | 0.060 |
Why?
|
| Ventricular Remodeling | 1 | 2004 | 53 | 0.060 |
Why?
|
| Antioxidants | 1 | 2006 | 237 | 0.060 |
Why?
|
| Pregnancy Complications, Cardiovascular | 1 | 2004 | 29 | 0.060 |
Why?
|
| Injections, Intravenous | 4 | 2004 | 141 | 0.060 |
Why?
|
| Arteriosclerosis | 1 | 2004 | 54 | 0.060 |
Why?
|
| Abnormalities, Multiple | 1 | 2006 | 167 | 0.060 |
Why?
|
| Swine Diseases | 1 | 2004 | 7 | 0.060 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2005 | 201 | 0.060 |
Why?
|
| Myocarditis | 1 | 1984 | 44 | 0.060 |
Why?
|
| Inflammation | 2 | 2007 | 602 | 0.060 |
Why?
|
| Enoxaparin | 1 | 2024 | 27 | 0.060 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2004 | 34 | 0.060 |
Why?
|
| Potassium Channels | 1 | 2004 | 32 | 0.060 |
Why?
|
| Edema | 1 | 2004 | 68 | 0.060 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2005 | 194 | 0.060 |
Why?
|
| Vasoconstrictor Agents | 1 | 2004 | 83 | 0.060 |
Why?
|
| Glomerular Filtration Rate | 2 | 2018 | 111 | 0.060 |
Why?
|
| Radiography | 3 | 2006 | 485 | 0.060 |
Why?
|
| Immunohistochemistry | 2 | 2005 | 983 | 0.050 |
Why?
|
| Sample Size | 1 | 2003 | 36 | 0.050 |
Why?
|
| Staphylococcus aureus | 1 | 2007 | 327 | 0.050 |
Why?
|
| Heart Aneurysm | 1 | 1983 | 13 | 0.050 |
Why?
|
| Health Policy | 2 | 2012 | 151 | 0.050 |
Why?
|
| Retroperitoneal Space | 1 | 2002 | 32 | 0.050 |
Why?
|
| C-Reactive Protein | 1 | 2003 | 143 | 0.050 |
Why?
|
| Methoxamine | 2 | 1993 | 4 | 0.050 |
Why?
|
| Internship and Residency | 1 | 2008 | 442 | 0.050 |
Why?
|
| Mitral Valve Prolapse | 1 | 1982 | 3 | 0.050 |
Why?
|
| Drug Synergism | 3 | 2007 | 150 | 0.050 |
Why?
|
| Renal Dialysis | 1 | 2003 | 170 | 0.050 |
Why?
|
| Morphine Derivatives | 1 | 2022 | 28 | 0.050 |
Why?
|
| Anesthesia | 1 | 2002 | 73 | 0.050 |
Why?
|
| Pain Clinics | 1 | 2001 | 3 | 0.050 |
Why?
|
| Hospital Units | 1 | 2001 | 10 | 0.050 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2001 | 44 | 0.050 |
Why?
|
| Hospitals | 1 | 2022 | 172 | 0.050 |
Why?
|
| Dogs | 3 | 1993 | 185 | 0.050 |
Why?
|
| Benchmarking | 2 | 2011 | 61 | 0.050 |
Why?
|
| Nitroglycerin | 3 | 2004 | 9 | 0.050 |
Why?
|
| Comprehensive Health Care | 1 | 2000 | 9 | 0.050 |
Why?
|
| Fluoroscopy | 2 | 1993 | 45 | 0.050 |
Why?
|
| Heart Arrest | 1 | 2002 | 149 | 0.050 |
Why?
|
| Autopsy | 1 | 2000 | 47 | 0.040 |
Why?
|
| Cardiology Service, Hospital | 1 | 2000 | 15 | 0.040 |
Why?
|
| Tissue Scaffolds | 1 | 2020 | 36 | 0.040 |
Why?
|
| Vitamins | 1 | 2000 | 64 | 0.040 |
Why?
|
| Arkansas | 2 | 2016 | 1982 | 0.040 |
Why?
|
| Amyloidosis | 2 | 1991 | 77 | 0.040 |
Why?
|
| Biocompatible Materials | 1 | 2020 | 68 | 0.040 |
Why?
|
| Public Policy | 2 | 2012 | 38 | 0.040 |
Why?
|
| Oxidative Stress | 1 | 2004 | 760 | 0.040 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2015 | 160 | 0.040 |
Why?
|
| Diastole | 2 | 1993 | 70 | 0.040 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2000 | 22 | 0.040 |
Why?
|
| Renal Artery Obstruction | 1 | 2000 | 22 | 0.040 |
Why?
|
| Lymphocytes | 2 | 1991 | 154 | 0.040 |
Why?
|
| Disease-Free Survival | 1 | 2000 | 452 | 0.040 |
Why?
|
| Hospitals, Public | 1 | 1999 | 7 | 0.040 |
Why?
|
| Placebos | 2 | 1990 | 84 | 0.040 |
Why?
|
| Carotid Stenosis | 1 | 2000 | 64 | 0.040 |
Why?
|
| Syndrome | 3 | 2006 | 237 | 0.040 |
Why?
|
| Morbidity | 1 | 1999 | 128 | 0.040 |
Why?
|
| Risk Adjustment | 1 | 2019 | 16 | 0.040 |
Why?
|
| Mice, Knockout | 2 | 2014 | 842 | 0.040 |
Why?
|
| Adolescent | 7 | 1996 | 6392 | 0.040 |
Why?
|
| Injections, Intralesional | 1 | 2018 | 31 | 0.040 |
Why?
|
| Quality of Health Care | 1 | 2000 | 184 | 0.040 |
Why?
|
| Internationality | 1 | 2018 | 41 | 0.040 |
Why?
|
| Patient Care Team | 1 | 2000 | 259 | 0.040 |
Why?
|
| Radiation Dosage | 1 | 2019 | 157 | 0.040 |
Why?
|
| Losartan | 1 | 1998 | 27 | 0.040 |
Why?
|
| Drug Evaluation | 2 | 1995 | 28 | 0.040 |
Why?
|
| Ventricular Pressure | 1 | 1997 | 16 | 0.040 |
Why?
|
| Administration, Intravenous | 1 | 2018 | 70 | 0.040 |
Why?
|
| Immunoblotting | 2 | 2008 | 117 | 0.040 |
Why?
|
| Health Services Needs and Demand | 1 | 1999 | 154 | 0.040 |
Why?
|
| Sex Characteristics | 1 | 1999 | 190 | 0.040 |
Why?
|
| Respiration | 2 | 1996 | 99 | 0.040 |
Why?
|
| Internal Mammary-Coronary Artery Anastomosis | 1 | 1997 | 5 | 0.040 |
Why?
|
| Radiation Monitoring | 1 | 2017 | 7 | 0.040 |
Why?
|
| International Cooperation | 2 | 2007 | 44 | 0.040 |
Why?
|
| Biopsy | 5 | 1994 | 591 | 0.040 |
Why?
|
| Calcium Channel Blockers | 1 | 1997 | 62 | 0.040 |
Why?
|
| Cardiomegaly | 2 | 1988 | 38 | 0.040 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2008 | 244 | 0.040 |
Why?
|
| Ventricular Function, Right | 1 | 1997 | 38 | 0.030 |
Why?
|
| Patient Compliance | 1 | 1998 | 230 | 0.030 |
Why?
|
| Hormones | 2 | 1987 | 57 | 0.030 |
Why?
|
| Isotonic Contraction | 1 | 1996 | 1 | 0.030 |
Why?
|
| Interferon-alpha | 1 | 1996 | 48 | 0.030 |
Why?
|
| Isometric Contraction | 1 | 1996 | 21 | 0.030 |
Why?
|
| Vascular Resistance | 3 | 1997 | 55 | 0.030 |
Why?
|
| Forearm | 1 | 1996 | 28 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 1998 | 583 | 0.030 |
Why?
|
| Mice | 3 | 2014 | 5671 | 0.030 |
Why?
|
| Italy | 1 | 2015 | 26 | 0.030 |
Why?
|
| Data Collection | 3 | 2011 | 283 | 0.030 |
Why?
|
| Carbon Dioxide | 1 | 1996 | 94 | 0.030 |
Why?
|
| Blood Flow Velocity | 1 | 2015 | 100 | 0.030 |
Why?
|
| Delivery of Health Care | 1 | 1998 | 308 | 0.030 |
Why?
|
| Phlebography | 1 | 2015 | 60 | 0.030 |
Why?
|
| Neurotransmitter Agents | 1 | 1995 | 35 | 0.030 |
Why?
|
| Cost Savings | 1 | 1995 | 58 | 0.030 |
Why?
|
| Radionuclide Angiography | 1 | 1994 | 2 | 0.030 |
Why?
|
| Tubulin Modulators | 1 | 2015 | 27 | 0.030 |
Why?
|
| Atherectomy, Coronary | 1 | 1994 | 6 | 0.030 |
Why?
|
| Monte Carlo Method | 1 | 1995 | 86 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2020 | 1568 | 0.030 |
Why?
|
| Decision Support Techniques | 1 | 1995 | 71 | 0.030 |
Why?
|
| Time | 1 | 2014 | 26 | 0.030 |
Why?
|
| Journal Impact Factor | 1 | 2014 | 7 | 0.030 |
Why?
|
| Liver Transplantation | 1 | 1996 | 149 | 0.030 |
Why?
|
| Kinetics | 2 | 1986 | 627 | 0.030 |
Why?
|
| Models, Cardiovascular | 2 | 2004 | 21 | 0.030 |
Why?
|
| Genetic Vectors | 1 | 2014 | 127 | 0.030 |
Why?
|
| Nervous System Diseases | 1 | 1995 | 88 | 0.030 |
Why?
|
| Fibrosis | 1 | 2014 | 178 | 0.030 |
Why?
|
| Pulmonary Circulation | 1 | 1993 | 34 | 0.030 |
Why?
|
| Monitoring, Physiologic | 1 | 2014 | 126 | 0.030 |
Why?
|
| Learning Curve | 1 | 2013 | 18 | 0.030 |
Why?
|
| Drug Monitoring | 1 | 1993 | 78 | 0.030 |
Why?
|
| Ischemic Attack, Transient | 1 | 2013 | 56 | 0.030 |
Why?
|
| Ultrasonics | 1 | 1993 | 31 | 0.030 |
Why?
|
| Jugular Veins | 1 | 1993 | 31 | 0.030 |
Why?
|
| Apoptosis | 2 | 2011 | 1102 | 0.030 |
Why?
|
| Cardiac Imaging Techniques | 1 | 2012 | 8 | 0.030 |
Why?
|
| Alprostadil | 1 | 1992 | 10 | 0.030 |
Why?
|
| Gene Expression Regulation | 2 | 2008 | 972 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 2 | 2008 | 1795 | 0.030 |
Why?
|
| Half-Life | 2 | 1998 | 86 | 0.030 |
Why?
|
| Tissue Survival | 1 | 2012 | 10 | 0.030 |
Why?
|
| Myocardial Perfusion Imaging | 1 | 2012 | 16 | 0.020 |
Why?
|
| Obesity | 1 | 2000 | 1101 | 0.020 |
Why?
|
| Smoking | 2 | 2011 | 505 | 0.020 |
Why?
|
| Endocardium | 2 | 1989 | 7 | 0.020 |
Why?
|
| Phosphodiesterase 3 Inhibitors | 1 | 2011 | 1 | 0.020 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2012 | 51 | 0.020 |
Why?
|
| Adrenergic beta-1 Receptor Antagonists | 1 | 2011 | 6 | 0.020 |
Why?
|
| Adrenergic beta-Agonists | 1 | 1991 | 41 | 0.020 |
Why?
|
| Health Status | 1 | 1993 | 298 | 0.020 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2011 | 57 | 0.020 |
Why?
|
| Goals | 1 | 1991 | 41 | 0.020 |
Why?
|
| Recovery of Function | 1 | 2012 | 187 | 0.020 |
Why?
|
| Diagnostic Imaging | 1 | 2012 | 177 | 0.020 |
Why?
|
| Mannitol | 1 | 1990 | 15 | 0.020 |
Why?
|
| Body Water | 1 | 1990 | 24 | 0.020 |
Why?
|
| Critical Care | 1 | 2012 | 213 | 0.020 |
Why?
|
| Dopamine | 1 | 1991 | 170 | 0.020 |
Why?
|
| Vasoconstriction | 1 | 1990 | 55 | 0.020 |
Why?
|
| Graft Survival | 1 | 1991 | 151 | 0.020 |
Why?
|
| Sodium | 1 | 1990 | 92 | 0.020 |
Why?
|
| Blood Volume | 1 | 1990 | 69 | 0.020 |
Why?
|
| Program Development | 1 | 2011 | 162 | 0.020 |
Why?
|
| Adrenergic beta-2 Receptor Antagonists | 1 | 2009 | 1 | 0.020 |
Why?
|
| Adrenergic beta-2 Receptor Agonists | 1 | 2009 | 2 | 0.020 |
Why?
|
| Transplantation, Homologous | 1 | 2009 | 138 | 0.020 |
Why?
|
| Liver | 1 | 1994 | 1110 | 0.020 |
Why?
|
| Isoquinolines | 1 | 2008 | 28 | 0.020 |
Why?
|
| Cell Death | 1 | 2009 | 175 | 0.020 |
Why?
|
| Serine | 1 | 2008 | 37 | 0.020 |
Why?
|
| Tyrphostins | 1 | 2008 | 9 | 0.020 |
Why?
|
| Janus Kinases | 1 | 2008 | 8 | 0.020 |
Why?
|
| Physical Exertion | 1 | 1988 | 44 | 0.020 |
Why?
|
| Selection Bias | 1 | 2008 | 15 | 0.020 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2008 | 73 | 0.020 |
Why?
|
| Pulse | 1 | 1988 | 14 | 0.020 |
Why?
|
| Pennsylvania | 3 | 1993 | 30 | 0.020 |
Why?
|
| Ischemic Preconditioning, Myocardial | 1 | 2007 | 2 | 0.020 |
Why?
|
| Organ Culture Techniques | 1 | 2007 | 48 | 0.020 |
Why?
|
| Bayes Theorem | 1 | 1988 | 105 | 0.020 |
Why?
|
| Creatine Kinase, BB Form | 1 | 2007 | 1 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2008 | 273 | 0.020 |
Why?
|
| Receptors, Purinergic P1 | 1 | 2007 | 8 | 0.020 |
Why?
|
| Survival | 1 | 2007 | 12 | 0.020 |
Why?
|
| Immunologic Factors | 1 | 2008 | 113 | 0.020 |
Why?
|
| Theophylline | 1 | 2007 | 21 | 0.020 |
Why?
|
| Pyridazines | 1 | 1987 | 11 | 0.020 |
Why?
|
| 5'-Nucleotidase | 1 | 2007 | 12 | 0.020 |
Why?
|
| Nitriles | 1 | 2007 | 52 | 0.020 |
Why?
|
| Renin-Angiotensin System | 1 | 1987 | 59 | 0.020 |
Why?
|
| Bundle-Branch Block | 1 | 1987 | 11 | 0.020 |
Why?
|
| Blood Coagulation | 1 | 2007 | 58 | 0.020 |
Why?
|
| Butadienes | 1 | 2007 | 47 | 0.020 |
Why?
|
| Models, Chemical | 1 | 2007 | 64 | 0.020 |
Why?
|
| Premedication | 1 | 2007 | 18 | 0.020 |
Why?
|
| Pain | 2 | 1982 | 374 | 0.020 |
Why?
|
| Evaluation Studies as Topic | 3 | 1992 | 108 | 0.020 |
Why?
|
| Drug Combinations | 1 | 2007 | 126 | 0.020 |
Why?
|
| Depression, Chemical | 1 | 1986 | 14 | 0.020 |
Why?
|
| Coenzymes | 1 | 2006 | 3 | 0.020 |
Why?
|
| Stimulation, Chemical | 1 | 1986 | 29 | 0.020 |
Why?
|
| Vasoactive Intestinal Peptide | 1 | 1986 | 19 | 0.020 |
Why?
|
| Heart Function Tests | 1 | 1986 | 11 | 0.020 |
Why?
|
| Fluid Therapy | 1 | 2007 | 75 | 0.020 |
Why?
|
| Oncogene Protein v-akt | 1 | 2006 | 10 | 0.020 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2008 | 205 | 0.020 |
Why?
|
| Alanine | 1 | 2006 | 41 | 0.020 |
Why?
|
| Phosphoric Monoester Hydrolases | 1 | 2006 | 21 | 0.020 |
Why?
|
| Receptors, Vasopressin | 1 | 2006 | 23 | 0.020 |
Why?
|
| Amidines | 1 | 2006 | 8 | 0.020 |
Why?
|
| Lactates | 1 | 1986 | 30 | 0.020 |
Why?
|
| Educational Measurement | 1 | 2008 | 204 | 0.020 |
Why?
|
| Benzylamines | 1 | 2006 | 15 | 0.020 |
Why?
|
| Sulfones | 1 | 2006 | 24 | 0.020 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2006 | 53 | 0.020 |
Why?
|
| Long-Term Care | 1 | 1986 | 50 | 0.020 |
Why?
|
| Research Design | 1 | 2008 | 343 | 0.020 |
Why?
|
| Models, Animal | 1 | 2006 | 229 | 0.020 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2006 | 72 | 0.020 |
Why?
|
| Heart Conduction System | 1 | 2005 | 23 | 0.020 |
Why?
|
| Nitric Oxide | 1 | 2007 | 254 | 0.020 |
Why?
|
| Diabetes Mellitus | 1 | 1989 | 281 | 0.020 |
Why?
|
| Osmotic Pressure | 1 | 1985 | 11 | 0.020 |
Why?
|
| Osmolar Concentration | 1 | 1985 | 63 | 0.020 |
Why?
|
| Safety | 1 | 2005 | 77 | 0.020 |
Why?
|
| Enzyme Inhibitors | 1 | 2007 | 378 | 0.020 |
Why?
|
| Aortography | 1 | 2004 | 35 | 0.010 |
Why?
|
| Glyburide | 1 | 2004 | 6 | 0.010 |
Why?
|
| Scleroderma, Systemic | 1 | 1984 | 6 | 0.010 |
Why?
|
| Anastomosis, Surgical | 1 | 2004 | 66 | 0.010 |
Why?
|
| Ventricular Fibrillation | 1 | 2004 | 16 | 0.010 |
Why?
|
| Anesthesia, Obstetrical | 1 | 2004 | 39 | 0.010 |
Why?
|
| Verapamil | 1 | 1984 | 22 | 0.010 |
Why?
|
| Models, Biological | 1 | 2007 | 722 | 0.010 |
Why?
|
| Vascular Surgical Procedures | 1 | 2006 | 164 | 0.010 |
Why?
|
| Statistics as Topic | 1 | 2004 | 87 | 0.010 |
Why?
|
| Patient Discharge | 1 | 2006 | 317 | 0.010 |
Why?
|
| Transcription Factors | 1 | 2007 | 558 | 0.010 |
Why?
|
| NG-Nitroarginine Methyl Ester | 1 | 2003 | 18 | 0.010 |
Why?
|
| Cesarean Section | 1 | 2004 | 159 | 0.010 |
Why?
|
| Pulmonary Artery | 1 | 1984 | 145 | 0.010 |
Why?
|
| Swine | 1 | 2004 | 398 | 0.010 |
Why?
|
| Endpoint Determination | 1 | 2002 | 24 | 0.010 |
Why?
|
| Thorax | 1 | 1982 | 16 | 0.010 |
Why?
|
| Anxiety Disorders | 1 | 1982 | 126 | 0.010 |
Why?
|
| Popliteal Artery | 1 | 2000 | 27 | 0.010 |
Why?
|
| Iliac Artery | 1 | 2000 | 34 | 0.010 |
Why?
|
| Hospitals, University | 1 | 1999 | 76 | 0.010 |
Why?
|
| Mortality | 1 | 1999 | 96 | 0.010 |
Why?
|
| Brain | 1 | 2006 | 1313 | 0.010 |
Why?
|
| Cross-Over Studies | 1 | 1998 | 219 | 0.010 |
Why?
|
| Dyspnea | 1 | 1977 | 74 | 0.010 |
Why?
|
| Abdomen | 1 | 1977 | 75 | 0.010 |
Why?
|
| Pregnancy | 1 | 2004 | 2469 | 0.010 |
Why?
|
| Physical Examination | 1 | 1977 | 93 | 0.010 |
Why?
|
| Fatigue | 1 | 1977 | 118 | 0.010 |
Why?
|
| Physical Fitness | 1 | 1997 | 54 | 0.010 |
Why?
|
| Walking | 1 | 1997 | 96 | 0.010 |
Why?
|
| Actuarial Analysis | 1 | 1996 | 9 | 0.010 |
Why?
|
| Hepatitis C | 1 | 1996 | 79 | 0.010 |
Why?
|
| Nitroprusside | 1 | 1992 | 11 | 0.010 |
Why?
|
| Neck | 1 | 1993 | 99 | 0.010 |
Why?
|
| Pilot Projects | 1 | 1995 | 700 | 0.010 |
Why?
|
| HLA Antigens | 1 | 1992 | 53 | 0.010 |
Why?
|
| Transplantation, Heterotopic | 1 | 1991 | 7 | 0.010 |
Why?
|
| Immunity, Cellular | 1 | 1991 | 69 | 0.010 |
Why?
|
| Regression Analysis | 1 | 1991 | 385 | 0.010 |
Why?
|
| Cyclosporine | 1 | 1991 | 65 | 0.010 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 1990 | 56 | 0.010 |
Why?
|
| Histocompatibility Testing | 1 | 1990 | 12 | 0.010 |
Why?
|
| Transplantation, Heterologous | 1 | 1989 | 75 | 0.010 |
Why?
|
| Cell Division | 1 | 1990 | 292 | 0.010 |
Why?
|
| Length of Stay | 1 | 1991 | 623 | 0.000 |
Why?
|
| Phenotype | 1 | 1990 | 727 | 0.000 |
Why?
|
| Bundle of His | 1 | 1987 | 8 | 0.000 |
Why?
|
| Atrial Flutter | 1 | 1987 | 9 | 0.000 |
Why?
|
| Cobalt | 1 | 1986 | 16 | 0.000 |
Why?
|
| Histological Techniques | 1 | 1986 | 9 | 0.000 |
Why?
|
| Endomyocardial Fibrosis | 1 | 1985 | 3 | 0.000 |
Why?
|
| Doxorubicin | 1 | 1986 | 233 | 0.000 |
Why?
|
| Thallium | 1 | 1984 | 6 | 0.000 |
Why?
|
| Radioisotopes | 1 | 1984 | 17 | 0.000 |
Why?
|
| Heart Defects, Congenital | 1 | 1990 | 583 | 0.000 |
Why?
|
| Microcirculation | 1 | 1984 | 71 | 0.000 |
Why?
|
| Radionuclide Imaging | 1 | 1984 | 116 | 0.000 |
Why?
|
| Infant | 1 | 1990 | 3565 | 0.000 |
Why?
|
| Child, Preschool | 1 | 1990 | 3872 | 0.000 |
Why?
|
| Child | 1 | 1990 | 6838 | 0.000 |
Why?
|